Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA044659 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA044659, RRID:AB_2679040
- Product name
- Anti-CD47
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CD47, Gene description: CD47 molecule, Alternative Gene Names: IAP, MER6, OA3, Validated applications: IHC, Uniprot ID: Q08722, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps
Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors
Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma
Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
A unique esophageal extracellular matrix proteome alters normal fibroblast function in severe eosinophilic esophagitis
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas
Shiratori-Aso S, Nakazawa D, Kudo T, Kanda M, Ueda Y, Watanabe-Kusunoki K, Nishio S, Iwasaki S, Tsuji T, Masuda S, Tomaru U, Ishizu A, Atsumi T
JCI Insight 2023;8(15)
JCI Insight 2023;8(15)
Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors
Zhang Y, Zhang D, An S, Liu Q, Liang C, Li J, Liu P, Wu C, Huang G, Wei W, Liu J
Research 2023;6
Research 2023;6
Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma
Liu X, Zhang H, Wang C, Li Z, Zhu Q, Feng Y, Fan J, Qi S, Wu Z, Liu Y
Current Neuropharmacology 2023;21(10):2159-2173
Current Neuropharmacology 2023;21(10):2159-2173
Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
Lang C, Lantos A, Megyesfalvi Z, Egger F, Hoda M, Mosleh B, Klikovits T, Oberndorfer F, Timelthaler G, Ferencz B, Fillinger J, Schwendenwein A, Querner A, Boettiger K, Renyi-Vamos F, Hoetzenecker K, Laszlo V, Schelch K, Dome B
ESMO Open 2022;7(6):100631
ESMO Open 2022;7(6):100631
CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
Cho J, Yoon S, Kim S, Ko Y, Kim W
Blood Advances 2022;6(24):6120-6130
Blood Advances 2022;6(24):6120-6130
A unique esophageal extracellular matrix proteome alters normal fibroblast function in severe eosinophilic esophagitis
Hsieh L, Chiang A, Duong L, Kuo C, Dong S, Dohil R, Kurten R, Lewis N, Aceves S
Journal of Allergy and Clinical Immunology 2021;148(2):486-494
Journal of Allergy and Clinical Immunology 2021;148(2):486-494
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Honkanen T, Tikkanen A, Karihtala P, Mäkinen M, Väyrynen J, Koivunen J
Scientific Reports 2019;9(1)
Scientific Reports 2019;9(1)
Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas
Verver D, Poirier-Colame V, Tomasic G, Cherif-Rebai K, Grunhagen D, Verhoef C, Suciu S, Robert C, Zitvogel L, Eggermont A
OncoImmunology 2019;8(11):e1660121
OncoImmunology 2019;8(11):e1660121
No comments: Submit comment
No validations: Submit validation data